Disciplined approach to drug discovery and early development

被引:66
|
作者
Plenge, Robert M. [1 ]
机构
[1] Merck Res Labs, Boston, MA 02115 USA
关键词
DEVELOPMENT PRODUCTIVITY; PHARMACEUTICAL-INDUSTRY; LESSONS; TARGETS; CHALLENGE; MEDICINES; ATTRITION; CANCER; RATES;
D O I
10.1126/scitranslmed.aaf2608
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Our modern health care system demands therapeutic interventions that improve the lives of patients. Unfortunately, decreased productivity in therapeutics research and development (R&D) has driven drug costs up while delivering insufficient value to patients. Here, I discuss a model of translational medicine that connects four components of the early R&D pipeline-causal human biology, therapeutic modality, biomarkers of target modulation, and proof-of-concept clinical trials. Whereas the individual components of this model are not new, technological advances and a disciplined approach to integrating all four areas offer hope for improving R&D productivity.
引用
收藏
页数:5
相关论文
共 50 条